Individualized Mini-Panel Sequencing of ctDNA Allows Tumor Monitoring in Complex Karyotype Sarcomas.
biomarker
cfDNA
complex karyotype sarcoma
ctDNA
leiomyosarcoma
liquid biopsy
myxofibrosarcoma
pleomorphic sarcoma
soft tissue sarcoma
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
06 Sep 2022
06 Sep 2022
Historique:
received:
08
08
2022
revised:
31
08
2022
accepted:
04
09
2022
entrez:
23
9
2022
pubmed:
24
9
2022
medline:
28
9
2022
Statut:
epublish
Résumé
Soft tissue sarcomas (STS) are rare tumors of mesenchymal origin with high mortality. After curative resection, about one third of patients suffer from distant metastases. Tumor follow-up only covers a portion of recurrences and is associated with high cost and radiation burden. For metastasized STS, only limited inferences can be drawn from imaging data regarding therapy response. To date there are no established and evidence-based diagnostic biomarkers for STS due to their rarity and diversity. In a proof-of-concept study, circulating tumor DNA (ctDNA) was quantified in (
Identifiants
pubmed: 36142126
pii: ijms231810215
doi: 10.3390/ijms231810215
pmc: PMC9499617
pii:
doi:
Substances chimiques
Biomarkers, Tumor
0
Cell-Free Nucleic Acids
0
Circulating Tumor DNA
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Deutsche Forschungsgemeinschaft
ID : 396168587
Organisme : Deutsche Forschungsgemeinschaft
ID : BR 5712/1-1
Organisme : Deutsche Forschungsgemeinschaft
ID : CL 427/4-1
Organisme : Deutsche Forschungsgemeinschaft
ID : EI 866/7-1
Organisme : Fördergesellschaft Forschung Tumorbiologie
ID : Liquid-Biopsy-Initiative
Organisme : Deutsche Forschungsgemeinschaft
ID : EI866/9-1
Organisme : Deutsche Forschungsgemeinschaft
ID : DFG SFB1479 (Project ID: 441891347- S1)
Organisme : Deutsche Forschungsgemeinschaft
ID : SFB1160 (Project Z02)
Organisme : Deutsche Forschungsgemeinschaft
ID : SFB1453 (Project ID 431984000 - S1)
Organisme : Deutsche Forschungsgemeinschaft
ID : TRR167 (Project Z01)
Organisme : German Federal Ministry of Education and Research
ID : MIRACUM, FKZ 01ZZ1801B
Références
Oncogene. 2003 Apr 10;22(14):2215-22
pubmed: 12687023
Cancers (Basel). 2022 Apr 21;14(9):
pubmed: 35565213
BMC Res Notes. 2019 Feb 27;12(1):106
pubmed: 30813969
Nat Commun. 2020 Jan 27;11(1):525
pubmed: 31988276
Genome Med. 2017 Apr 19;9(1):34
pubmed: 28420421
Cell. 2017 Nov 2;171(4):950-965.e28
pubmed: 29100075
Nucleic Acids Res. 2010 Sep;38(16):e164
pubmed: 20601685
Sci Transl Med. 2017 Aug 16;9(403):
pubmed: 28814544
Br J Cancer. 2014 May 13;110(10):2420-6
pubmed: 24736584
Ann Oncol. 2021 Nov;32(11):1348-1365
pubmed: 34303806
Nat Med. 2019 Dec;25(12):1928-1937
pubmed: 31768066
Genes (Basel). 2021 Sep 23;12(10):
pubmed: 34680867
Cancer Sci. 2009 Sep;100(9):1573-80
pubmed: 19555393
Crit Rev Oncol Hematol. 2018 Jun;126:1-5
pubmed: 29759550
Nature. 2020 May;581(7809):434-443
pubmed: 32461654
Bioinformatics. 2014 Aug 1;30(15):2114-20
pubmed: 24695404
Int J Cancer. 2019 Aug 15;145(4):1148-1161
pubmed: 30779112
Int J Clin Exp Pathol. 2010 Apr 23;3(4):416-28
pubmed: 20490332
Pathology. 2008 Oct;40(6):547-52
pubmed: 18752119
Scand J Clin Lab Invest. 2021 Jul;81(4):276-281
pubmed: 33999736
Clin Cancer Res. 2021 Nov 1;27(21):5922-5930
pubmed: 34426444
PLoS Biol. 2011 Jul;9(7):e1001091
pubmed: 21750661
Mol Cancer. 2022 Feb 14;21(1):50
pubmed: 35164780
Biomark Res. 2021 Jul 2;9(1):52
pubmed: 34215324
Nat Methods. 2015 May;12(5):423-5
pubmed: 25849638
Nat Rev Cancer. 2017 Apr;17(4):223-238
pubmed: 28233803
Int J Cancer. 2017 May 15;140(10):2344-2350
pubmed: 28205231
Genome Res. 2012 Mar;22(3):568-76
pubmed: 22300766
Bioinformatics. 2009 Aug 15;25(16):2078-9
pubmed: 19505943
Clin Cancer Res. 2018 Jun 1;24(11):2688-2699
pubmed: 29463554
Nat Biotechnol. 2016 May;34(5):547-555
pubmed: 27018799
Nat Med. 2008 Sep;14(9):985-90
pubmed: 18670422